Navigation Links
Essentialis Files Two New Patent Applications for Investigational Compound DCCR
Date:2/29/2012

SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Essentialis, Inc. announced the February 27, 2012 filing of two new patent applications expanding the patent portfolio claiming its investigational triglyceride-lowering compound DCCR and new methods of using the drug.  The first is a continuation-in-part of a current application that includes data from the recently completed clinical trial, CT013; the second is a patent filing covering certain aspects of the use of DCCR in the treatment of very high triglycerides (VHTG).  The filing is the fourth patent application filed by Essentialis covering DCCR, and has the potential to extend patent protection on the product to 2033.  Essentialis already holds composition of matter protection for DCCR through 2028.

"With our portfolio of issued and pending patents, we already have very solid protection and these new applications will make our protection even stronger," said Aaron D. Berg, President and Chief Executive Officer, Essentialis, Inc. "We are targeting 2015 market availability for DCCR, and it is our hope to receive patent protection through 2033."

Essentialis already has two issued US patents (7,572,789 and 7,799,777) providing composition of matter protection to DCCR to 2028 and two granted European patents (EP1781265 and EP1968601) providing similar protection.  With the recent filings, Essentialis is prosecuting eight US patent applications.  The company is prosecuting these filings in all major pharmaceutical markets.  The current protection on the product includes claims to the active ingredient, pharmaceutical formulations, methods of manufacture, and a wide range of methods to treat multiple diseases.  In particular, the claims cover methods to treat dyslipidemia including co-formulation and co-administration with a range of drugs currently used in the treatment of patients with lipid disorders.  

About DCCR
DCCR is a proprietary crystalline salt of diazoxide in a controlled-release, once-a-day tablet formulation. It is in development for patients with very high triglyceride (TG) levels. Essentialis has completed an End-of-Phase 2 meeting with the FDA and has obtained an SPA covering a pivotal study. Essentialis expects to initiate Phase 3 clinical trials in 2012. DCCR is covered by multiple issued US and granted EU patents, which provide composition of matter protection until 2028. Essentialis has evaluated DCCR in several double-blind, placebo-controlled studies which demonstrated that the drug was well tolerated and that statistical significance for various endpoints was achieved in patients with elevated triglycerides. More than 100,000 patient-years of treatment with diazoxide help support the acceptable safety of DCCR.

About Essentialis, Inc.
Essentialis is a San Diego-headquartered pharmaceutical company focused on the development of breakthrough medicines targeted to the ATP-sensitive potassium channel, a metabolically regulated membrane protein whose modulation has potential to treat and prevent a wide range of cardiovascular and metabolic diseases. For more information visit http://essentialistherapeutics.com/

Contacts:

Kristie Kuhl
kkuhl@makovsky.com 
212.508.9642

Or

Aaron Berg 
aberg@essentialistherapeutics.com 
858-964-5022


'/>"/>
SOURCE Essentialis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
2. Essentialis Promotes Aaron Berg to Chief Executive Officer
3. Essentialis Strengthens Patent Protection of Its Novel ATP-Sensitive Potassium Channel Opener Portfolio
4. Essentialis to Submit SPA for Hypertriglyceridemia
5. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
6. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
7. Bionovo Files Registration Statement for Offering of Convertible Preferred Stock and Warrants
8. ReBuilder (RBRM) Files Complaints Against Stock Traders
9. Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
10. Natural Alternatives International, Inc. Files Patent Infringement Claim Against DNP International Co., Inc.
11. Department of Justice files consent decree of permanent injunction against Ranbaxy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):